Technology

Our technology platforms can lead to products that are easier to use for patients and caregivers while reducing costs for payors and the health care system.

The Xeris Solution for Conventional Formulation Limitations

Our proprietary

XeriSol™ XeriJect™

Non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions and suspensions formulated using our technology have high stability and solubility.

HIGH STABILITY

NO reconstitution

Ready-to-use injectable with a straightforward administration.

NO refrigeration

Room-temperature stability, no refrigeration required.

HIGH SOLUBILITY

SMALLER injection volumes

Small injection volumes due to non-aqueous formulation.

CONVENIENT administration

Qualities allow for subcutaneous (SC) or intramuscular (IM) administration.

Our biocompatible non-aqueous injectable solutions and suspensions can be packaged for administration in various commercially available ways:

Vial
Single-use auto-injector
Prefilled syringe
Multi-dose pen
Infusion pump

XeriSolTM can be used for SMALLER molecules

Our proprietary XeriSol™ and XeriJect™ non-aqueous formulation technology platforms are designed to address the limitations of aqueous formulations for certain drugs. The solutions and suspensions formulated using our technology have high stability and solubility.

How it works

  1. An aqueous formulation of a peptide or small molecule is created at an optimal, specific pH. This allows the peptide or small molecule to remain soluble at high concentrations in water.
  2. The solution is dried into a powder and reconstituted in an aprotic, polar (FDA-approved) liquid. The liquid prevents aggregation and fibrillation of the drug substance.
  3. When a ready-to-use XeriSol formulation is injected into a patient, it is effectively placed back into a water environment, where it behaves appropriately.

XeriJectTM can be used for LARGER molecules

The XeriJect formulation technology is best suited for drugs and biologics including large molecules such as proteins, monoclonal antibodies, and vaccines.

How it works

  1. Specialized drying or particle engineering techniques are employed to create powders.
  2. The powders are “wetted” with biocompatible diluents, creating ultra-concentrated, low-volume paste formulations.
  3. The paste formulations are administered via IM or SC using commercially available pens and pumps.

Using XeriJect, we have formulated suspensions with a protein concentration in excess of 400 mg/mL, far exceeding current aqueous formulation systems with maximum achievable protein concentrations of 50–250 mg/mL. Our technology platforms can lead to products that are easier to use for patients and caregivers while reducing costs for payors and the health care system.

Conventional Formulation Limitations

Injectable pharmaceuticals typically rely on liquid (water) to deliver drugs and biologics, but many drugs have low solubility in water and are not stable. There are a number of conventional approaches to addressing these barriers.

LOW STABILITY

Reconstitution

Products are freeze-dried into a powder that must be reconstituted with a liquid diluent prior to use. This is often a challenging multi-step procedure, especially in emergency situations.

Refrigeration

Reconstituted products may either need to be used immediately or refrigerated because they begin to break down once combined with water.

LOW SOLUBILITY

Complicated formulations

Products may require complicated formulation volumes to make them soluble.

LARGE injection volumes

Products may require injection volumes that are too large for SC or IM delivery and therefore necessitate intravenous (IV) infusion.